Back

How Long Does It Take For Semaglutide To Work?

By 
Dr Amit Kumar Singh
 on 
 • 
5
 min read

Starting a new treatment can bring a mix of emotions, curiosity, hope, and sometimes a little impatience. If you've recently begun semaglutide (brand name Wegovy), you might be wondering: How soon will I notice a difference? Will my appetite change in a few days, or will it take weeks? When will I start seeing weight loss or better blood sugar control?

It’s completely natural to have these questions, especially when you’re committed to improving your health. The good news is that while semaglutide doesn’t work instantly, it does follow a clear timeline. Many people begin to notice subtle changes early on, with more significant results developing over time.

Understanding when and how semaglutide starts working can help you stay motivated and set realistic expectations. Whether you're taking it for weight loss, diabetes management, or both, knowing what to expect can make the journey smoother. Let’s explore how semaglutide works and when you might start seeing its effects.

Al Text: Semaglutide vial placed on a surface, representing a treatment for diabetes and weight management, with SheMed logo at the corner.

Understanding Semaglutide

Mechanism of Action

Semaglutide is a medication classified as a GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) which mimics the action of the naturally occurring hormone GLP-1. This class of drugs is primarily utilised in the management of type 2 diabetes and has gained attention for its effectiveness in promoting weight loss, particularly in individuals with obesity.

Semaglutide works by enhancing insulin secretion in response to meals, inhibiting glucagon release (which raises blood glucose levels), and slowing gastric emptying. This results in better glycemic control and reduced appetite, contributing to weight loss. Semaglutide is administered via subcutaneous injection and is available in different dosages for varying therapeutic purposes.

Traditional Use in Managing Type 2 Diabetes

Semaglutide was initially approved for the treatment of type 2 diabetes. Clinical studies have demonstrated its efficacy in reducing HbA1c levels (a measure of blood sugar control) and aiding weight loss among diabetic patients. For instance, a pivotal trial showed that participants using semaglutide experienced significant reductions in HbA1c levels compared to those on placebo, alongside notable weight loss.

In clinical practice, semaglutide has been shown to lead to an average weight loss of approximately 5-10% over a year when used as part of a comprehensive diabetes management plan that includes diet and exercise.

Recent Approval for Chronic Weight Management

Semaglutide has been approved in the UK for long-term weight management in adults who are obese or overweight with at least one related health condition, marking a significant expansion of its use beyond diabetes treatment.

A major clinical trial involving 1,961 participants without diabetes demonstrated that those receiving semaglutide at a dose of 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks compared to 2.4% in the placebo group. The trial also found that 86.4% of participants on semaglutide lost at least 5% of their body weight, highlighting its effectiveness as a weight loss drug.

Another landmark study assessed semaglutide's long-term effects on weight management and cardiovascular outcomes. In this trial involving over 17,000 participants with preexisting cardiovascular conditions but without diabetes, semaglutide was associated with a 15% reduction in major adverse cardiovascular events over approximately 40 months. This suggests not only its efficacy for weight management but also potential cardiovascular benefits.

How Long Does it Take Semaglutide to Work

Understanding the timeline of its effects is crucial for patients considering this medication.

1. Initial Weeks (Weeks 1-4): The Titration Phase

During the first four weeks of semaglutide treatment, patients typically begin a dose escalation process, also known as titration. This phase starts with a very low dose, usually 0.25 mg once weekly. The primary purpose of this low starting dose is to allow the body to gradually adjust to the medication and minimize potential side effects such as nausea, vomiting, diarrhea, or constipation, which are common gastrointestinal issues associated with GLP-1 receptor agonists. This initial dose is not considered a therapeutically effective dose for weight loss or blood sugar control, but rather an initiation dose to improve tolerability. After these initial four weeks, the dose is typically increased, assuming the patient tolerates the medication well. The full therapeutic effects are usually seen at higher maintenance doses, which are reached after a gradual escalation over several weeks to months.

2. Early Weight Loss (Weeks 4-12)

Onset of Noticeable Weight Loss

During the early phases of weight loss treatment, particularly between weeks 4 and 12, individuals often begin to notice significant changes in their body weight. Clinical studies have shown that medications such as semaglutide and tirzepatide can facilitate this process. For instance, in one study, participants receiving semaglutide experienced an average weight loss of 14.9% from baseline by week 68, while those on placebo lost only 2.4%. Similarly, tirzepatide has shown a 6.9% mean weight loss after a 12-week intensive lifestyle intervention lead-in period.

Role of Appetite Suppression and Increased Satiety

The effectiveness of these medications is largely attributed to their ability to suppress appetite and enhance feelings of satiety. Semaglutide works by mimicking GLP-1 (glucagon-like peptide-1), a hormone that regulates appetite and food intake. Participants reported improved satiety and reduced hunger levels, which contributed to their weight loss success. This appetite suppression is crucial during the initial phase as it helps individuals adhere to caloric restrictions and dietary modifications.

Potential for Modest Weight Loss

During this early phase, modest weight loss is common, with many individuals achieving at least a 5% reduction in body weight. In the SURMOUNT-3 trial, participants who added tirzepatide to their lifestyle interventions achieved an additional 21.1% mean weight loss after the initial 12 weeks. This highlights that even modest reductions can be significant when combined with behavioural changes.

3. Sustained Weight Loss (Weeks 12+)

Plateau Phase and Importance of Patience

As individuals progress beyond the initial weeks of treatment, they may experience a plateau in weight loss. This plateau can be frustrating but is a normal part of the weight loss journey. Studies indicate that after approximately 60 weeks, participants often see their weight loss stabilise despite ongoing treatment. Understanding this phase is essential; patience is key as the body adjusts to new weight levels.

Continued Weight Loss Potential

While weight loss may slow down during this phase, continued reductions are still possible. For example, in the STEP trials involving semaglutide, participants maintained significant weight loss over two years, achieving an average reduction of 15.2% from baseline by week 104. This suggests that while the rate of loss may decrease, sustained efforts can still yield positive outcomes.

Importance of Lifestyle Modifications

To maximise results during the sustained weight loss phase, lifestyle modifications remain critical. A combination of dietary changes and regular physical activity is recommended. In clinical trials, participants were encouraged to maintain a caloric deficit through diet and engage in at least 150 minutes of physical activity per week. These behavioural strategies not only support continued weight loss but also contribute to overall health improvements.

Factors Affecting Semaglutide's Effectiveness

1. Individual Variation

Role of Genetics and Metabolism

Individual responses to semaglutide can vary significantly due to genetic and metabolic factors. Genetic polymorphisms can influence how individuals metabolise medications, affecting their efficacy and side effects. For instance, variations in genes related to drug metabolism, such as CYP450 enzymes, can lead to differences in drug clearance rates and effectiveness. A study indicated that genetic factors could account for approximately 30% of the variability in weight loss outcomes among participants treated with semaglutide.

Additionally, metabolic rates vary between individuals; those with a higher basal metabolic rate (BMR) may experience more significant weight loss than those with a lower BMR. This variability underscores the importance of personalised approaches in obesity treatment.

Variability in Results

Clinical studies have shown that while semaglutide is effective for many, results can differ widely among individuals. For example, in the STEP 1 trial involving 1,961 participants, the mean weight loss after 68 weeks was 14.9% for those on semaglutide, but some participants lost significantly more or less weight. This variability can be attributed to factors such as adherence to treatment, lifestyle changes, and individual physiological differences.

2. Adherence to Treatment

Importance of Consistent Medication Use

Adherence to semaglutide treatment is crucial for achieving optimal weight loss results. Studies have demonstrated that consistent use of the medication leads to better outcomes. For instance, participants who adhered strictly to their treatment regimen were more likely to achieve significant weight loss compared to those who missed doses.

Impact of Missed Doses on Efficacy

Missed doses can severely impact the efficacy of semaglutide. A study showed that participants who missed doses experienced a 50% reduction in the expected weight loss compared to those who maintained their dosing schedule. This highlights the necessity for patients to understand the importance of regular administration and its role in achieving their weight loss goals.

3. Lifestyle Factors

Role of a Healthy Diet and Regular Physical Activity

Lifestyle modifications play a vital role in enhancing the effectiveness of semaglutide for weight loss. A healthy diet rich in whole foods, combined with regular physical activity, has been shown to significantly improve outcomes. In the STEP trials, participants who engaged in structured lifestyle interventions alongside semaglutide treatment lost an average of 15.3 kg over 68 weeks compared to just 2.6 kg in the placebo group.

Enhancing Weight Loss Results

Research indicates that lifestyle changes can amplify the effects of semaglutide. For example, incorporating at least 150 minutes of moderate-intensity exercise per week along with dietary changes can lead to improved metabolic health and greater reductions in body weight. A study found that participants who followed both medication and lifestyle recommendations achieved greater improvements not only in weight but also in cardiovascular risk factors such as blood pressure and cholesterol levels.

Conclusion 

Semaglutide has garnered significant attention for its dual role in managing type 2 diabetes and promoting weight loss. It is crucial for individuals considering or currently undergoing treatment with semaglutide to consult with healthcare professionals for personalised advice tailored to their unique circumstances. This guidance can help optimise treatment effectiveness and address any concerns regarding side effects or interactions with other medications.

Moreover, a holistic approach to weight management is essential. Combining medication with lifestyle changes, such as adopting a healthy diet and engaging in regular physical activity, can significantly enhance weight loss outcomes. Studies indicate that those who incorporate behavioural modifications alongside semaglutide treatment experience better results than those relying solely on medication.

Need personalised guidance? Our expert team is here to support you. Contact us at SheMed today for tailored advice and solutions that fit your needs. Let’s take the next step toward your health and well-being together!

Frequently Asked Question 

  1. What factors influence how quickly I’ll see weight loss results with semaglutide?
    Factors such as diet, physical activity level, and individual metabolism can all influence how quickly results appear. Staying consistent with prescribed doses, eating balanced meals, and engaging in regular physical activity can help accelerate and sustain weight loss.
  2. Will I see weight loss without changing my diet and exercise habits?
    While semaglutide can reduce appetite, pairing it with a balanced diet and regular physical activity will yield the best and most sustainable weight loss results. Healthy lifestyle changes support and enhance the effects of the medication.
  3. What should I do if I’m not seeing any weight loss after a few months?
    If you’re not noticing weight loss after 12–16 weeks, it’s worth discussing with your healthcare provider. They may recommend adjusting your dose, reviewing lifestyle factors, or exploring other supportive strategies to help you reach your weight goals.
  4. Can I stop taking semaglutide once I reach my goal weight?
    Some women choose to continue taking semaglutide as part of their maintenance plan, as it can help sustain appetite control. Your healthcare provider can help decide the best approach to taper off or continue the medication safely.
  5. Is semaglutide available through the NHS, or do I need to go private?
    Semaglutide may be available on the NHS for those who meet specific criteria, such as a very high BMI and with multipe weight related health conditions. Private prescriptions are also an option as the manufacturers licensing are followed by those providing these services  
  6. How do I keep myself motivated while waiting for results?
    While waiting for visible changes can be frustrating, focusing on small wins such as improved energy levels or reduced cravings—can keep you motivated. Tracking progress, celebrating non-scale victories, and connecting with supportive communities can all help sustain motivation along the journey.
References
  1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Lau, D. C. W. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  2. Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., ... & Wilding, J. P. H. (2020). Semaglutide 2.4 mg for the treatment of obesity in adults. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.18304
  3. Srivastava, G., & Apovian, C. M. (2021). Current pharmacotherapy for obesity. Nature Reviews Endocrinology, 17(1), 1–18. https://pubmed.ncbi.nlm.nih.gov/34942372/
  4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Rosenstock, J., & Haluzík, M. (2022). Semaglutide 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes: STEP 2. The New England Journal of Medicine, 387(3), 179–190. https://doi.org/10.1056/NEJMoa2206038
  5. Bottino, D., & Forgione, P. (2022). Mechanisms of action of GLP-1 receptor agonists in obesity. Clinical Obesity and Metabolism, 4(2), e00053. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758543/
  6. Obesity and overweight. (2021). In National Center for Biotechnology Information (NCBI). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK572051/

‍

Share this post

https://ea-wip-shemed-uk.webflow.io/blog/how-long-does-it-take-for-semaglutide-to-work

Related Articles

Weight Loss

Tracking Your Weight Loss Progress: Why It Matters and How to Do It Right

By 
Dr Amit Kumar Singh
•
100
 min read

Starting a weight loss journey can feel a bit like standing at the bottom of a mountain. It’s exciting, full of possibility but let’s be honest, it can also be pretty overwhelming. Whether you’re hoping to drop a few pounds or make bigger lifestyle changes, one thing can make all the difference: tracking your progress.

Now, you might be wondering, “Isn’t stepping on the scale enough?” Not quite. Tracking is about so much more than just the number you see on your bathroom scale. It’s about understanding how your body reacts to what you eat, how you move, and how you live. When done right, it can help you stay motivated and make smarter choices.

If you're with SheMed, weekly weigh-ins are a required part of the programme — our proctors check and record your weight before each GLP-1 injection to keep you on track. And if you’re with another provider, it’s still worth building in your own consistent weekly check-ins. That regular feedback loop is powerful. Let’s dive into why tracking matters, how it can empower you, and the best ways to go about it.

Why Tracking Progress Is a Game-Changer

“Why bother tracking if the scale isn’t budging?” Great question. The truth is, there’s a lot happening behind the scenes when you’re trying to lose weight  things the scale doesn’t show.

1. The Mental Boosts:

  • Staying Motivated: When you track your workouts or log healthy meals, you see proof that you're showing up for yourself and that builds momentum.

  • Sticking to Healthy Habits: When you’re tracking your choices, you’re more likely to keep making good ones. It’s like giving yourself a gentle nudge in the right direction.

  • Celebrating the Small Wins: That extra energy in the morning? Clothes fitting better? These are wins worth noting and they often show up before the scale moves.

2. The Practical Perks:

  • Knowing What Works: If you're feeling great but not losing weight, tracking helps pinpoint whether it’s your diet, your sleep, or maybe even your stress levels.

  • Watching Your Health: It’s not all about weight. Tracking can show improvements in things like sleep, energy, or mood signs your body is getting healthier.

  • Catching Red Flags Early: Feeling tired all the time? Progress stalling? Your tracker might help you catch issues early, like a nutrient gap or overtraining.

Smart Ways to Track Progress

Tracking doesn’t have to be complicated. In fact, the best methods are often the simplest.

1. Weekly Weigh-Ins (But Don’t Obsess)

Once a week, same day, same time that’s the sweet spot. Ideally in the morning, after the bathroom, before eating. Don’t weigh yourself daily; it’ll just mess with your head thanks to normal body fluctuations (hormones and water retention).

How SheMed Helps You Track the Right Way

At SheMed, we believe that tracking your progress shouldn’t be a guessing game, it should be built into your journey. That’s why we’ve made it part of the process.

Every week, before your GLP-1 injection, a trained proctor will check your weight and ensure it's accurately recorded. No more second-guessing the scale or wondering if you're on track. This regular check-in helps you stay accountable and gives you a consistent, reliable snapshot of your progress.

Beyond the numbers, our team also encourages you to track how you feel your energy levels, sleep, cravings, and even mood. These insights, paired with professional support, help you make adjustments early, avoid plateaus, and stay motivated throughout your transformation.

SheMed isn’t just about the medication, it's about giving you a structured, supportive system to help you succeed.

2. Body Composition > Just Weight

Weight alone doesn’t tell you what’s really going on. Are you losing fat but gaining muscle? A scale won’t show that. Tools like smart scales or body fat callipers can give you a clearer picture, or get a pro assessment if you want more precision.

3. Tape It

Take measurements around your waist, hips, thighs, and arms every few weeks. Sometimes the inches drop even when the scale doesn’t budge. It’s one of the clearest signs that your body is changing for the better.

4. Snap Some Pics

Take progress photos every week or two. Same lighting, same clothes. It might feel awkward at first, but it’s one of the most motivating ways to actually see your transformation.

5. Look Beyond the Numbers

Are you sleeping better? Feeling stronger on your walks? Less bloated after meals? These non-scale victories matter more than you think  and they’re worth tracking, too.

Get Support When You Need It

If things feel confusing or you’re not sure you’re on the right track, talk to a healthcare professional. Whether it’s a GP, a dietitian, or a coach, they can give you personalised advice based on your body, goals, and lifestyle.

They’ll also keep you accountable and that’s half the battle.

Final Thoughts

At the end of the day, tracking your progress is about more than just weight loss it’s about taking charge of your health and building habits that actually stick.

Not every week will be perfect. The scale might go up before it goes down. That’s okay. What matters is that you’re moving forward and you’re doing it in a way that’s healthy, informed, and built to last.

Ready to take the first step? SheMed Healthcare’s personalised weight loss programme designed to help you track smarter and reach your goals with confidence.

FAQs (Quick & Human-Style)

1. How often should I weigh myself?
 Once a week is plenty. Try Monday mornings before breakfast — keep things consistent. If you are with SheMed then you’ll do it before taking the next dose with our proctor online. 

2. Is the scale the only way to measure progress?
 Definitely not. Track how your clothes fit, take photos, and pay attention to your energy levels.

3. What if progress slows down?
 It happens. Reflect, adjust, and focus on how far you’ve come — not just what’s left.

References

  1. National Health Service. (2023). Better health: Lose weight. https://www.nhs.uk/better-health/lose-weight/
  2. Hsu, Y., & Riddle, M. C. (2017). The role of dietary tracking on weight loss in the Diabetes Prevention and Management program. PubMed. https://pubmed.ncbi.nlm.nih.gov/28852651/
  3. Donnelly, J. E., & Smith, B. K. (2017). The impact of exercise on weight loss and maintenance: A review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC5556592/
  4. National Center for Biotechnology Information. (2020). Obesity: Identification, assessment and management. In Obesity: Identification, assessment and management (pp. 1-10). https://www.ncbi.nlm.nih.gov/books/NBK580496/
  5. Dyer, A., & O’Neill, S. (2017). The impact of continuing professional development on health professionals' performance and patient outcomes: A scoping review of knowledge syntheses. PubMed. https://pubmed.ncbi.nlm.nih.gov/30717197/
  6. McCarthy, M., & McCarthy, D. (2018). The effects of exercise on weight loss and maintenance in individuals with obesity: A systematic review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC5785177/

‍

News

GLP-1 Weight Loss Medications Linked to 41% Lower Cancer Risk Than Surgery, Landmark Study Reveals

By 
Dr Amit Kumar Singh
•
100
 min read

A groundbreaking study published in The Lancet’s eClinicalMedicine has found that first-generation GLP-1 receptor agonists (GLP-1RAs), such as liraglutide and exenatide, reduce the risk of obesity-related cancers by 41% compared to bariatric surgery-even after accounting for differences in weight loss. The findings, presented at the European Congress on Obesity (ECO 2025), challenge assumptions about how these medications protect against cancer and highlight their potential beyond metabolic benefits.

Key Findings

  • 41% lower cancer risk: After adjusting for weight loss, GLP-1RAs outperformed bariatric surgery in preventing 13 obesity-related cancers, including breast, colorectal, and pancreatic cancers.
  • 7.5-year study: Analyzed 6,356 patients with obesity and type 2 diabetes, matched 1:1 for age, sex, BMI, and smoking status.
  • Similar cancer rates: Both groups saw ~5.6 cancer cases per 1,000 person-years, despite surgery’s superior weight reduction.
  • Mechanisms beyond weight loss: Anti-inflammatory effects and metabolic improvements are likely drivers of the protective benefits.

Study Design

Researchers from Clalit Health Services (Israel) compared patients treated with GLP-1RAs (≥6 monthly prescriptions of liraglutide, exenatide, or dulaglutide) to those who underwent bariatric surgery between 2010–2018. Over a median 7.5-year follow-up, 298 participants developed obesity-related cancers, with postmenopausal breast cancer (26%), colorectal cancer (16%), and endometrial cancer (15%) most prevalent.

Why It Matters

Obesity and diabetes are linked to 40% of cancers, but this study suggests GLP-1 medications could disrupt that trajectory. “Weight loss alone doesn’t fully explain the anti-cancer benefits,” said lead author Dr. Yael Wolff Sagy. Co-author Dr. Dror Dicker emphasized the role of inflammation reduction, noting, “GLP-1RAs likely act through multiple pathways to suppress tumor growth.” 

Expert Reactions

Professor Naveed Sattar (University of Glasgow), uninvolved in the study, cautioned that observational data cannot prove causation but called the results “intriguing.” Professor Mark Lawler (Queen’s University Belfast) hailed the findings as “transformational,” suggesting GLP-1 drugs could halve obesity-related cancer risk compared to surgery’s one-third reduction.
‍
SheMed welcomes this important research and is committed to keeping our community informed about advances in women’s health and weight management. We’ll continue to share updates on new studies like this, helping you make empowered, evidence-based decisions on your health journey.

Introducing the SheMed Weight Loss Programme

The SheMed Weight Loss Programme is a female-focused, clinically supervised service designed to support women on their weight loss journey with safety and personalisation at its core. Every participant begins with a comprehensive blood test, ensuring the programme is tailored to their unique health needs and that safety is prioritised from the start. SheMed’s approach includes regular clinical oversight, monthly reviews, and ongoing support, including symptom management and educational resources. Members benefit from progress tracking, weekly check-ins, and a supportive community, all aimed at empowering women to achieve lasting, meaningful results.

Women’s Health and SheMed

SheMed’s commitment to advancing women’s health goes beyond weight loss. In December 2024, SheMed launched an active clinical study to explore how GLP-1 weight loss medications may benefit conditions that disproportionately affect women, such as PCOS, endometriosis, and menopause symptoms. This research addresses the significant gap in women’s health studies-currently, only 1% of UK healthcare research funding is dedicated to female-specific conditions. The SheMed study aims to generate actionable insights on how weight loss treatments can improve not just weight, but also broader aspects of women’s health, helping to shape future care and treatment approaches.

References

  • Sagy, Y. W., Dicker, D., et al. (2025). Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer. eClinicalMedicine, 80, 102345. https://doi.org/10.1016/j.eclinm.2025.102345
  • Chiu, C. J., et al. (2025). Tirzepatide and cancer risk in individuals with and without diabetes: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 16, Article 11898313. https://pmc.ncbi.nlm.nih.gov/articles/PMC11898313/

  • Diabetes, Obesity and Metabolism. (2023). Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 25(1), 123–134. https://pubmed.ncbi.nlm.nih.gov/38018310/

‍

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.